A 2-part, noninterventional, multicenter, multinational, open- label, prospective phase 4 study of eRbitux in combination with chemotherapy in patients with first-line management of metastatic colorectal cancer
Latest Information Update: 13 Oct 2017
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms SECURE
- 13 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress